AbbVie, Parkinson's disease

AbbVie drug succeeds in another Parkinson’s trial
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers including Adam Feuerstein,
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.
AbbVie Says Phase 3 TEMPO-2 Study Of Tavapadon In Early Parkinson's Disease Met Main Goal
Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the
Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, late-stage study showed that the drug significantly improved the ability of patients to manage daily tasks such as walking and eating.
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study
AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration approval of the drug in 2025. AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
Crain's Chicago Business18h
After one disappointment, AbbVie gets good news out of Cerevel buy
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
BioSpace2d
A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
The Pharma Letter1d
AbbVie Phase III success with tavapadon in Parkinson’s
US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...
AbbVie reports ‘positive’ results from Phase 3 TEMPO-2 trial
AbbVie (ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose ...